Skip to content

Additional treatment of Helicobacter Pylori infection on the severity of headaches in patients with idiopathic headache

Evaluation of additional treatment of Helicobacter Pylori infection on the severity of headaches in patients with idiopathic headache

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201109046056N3
Enrollment
210
Registered
2011-09-14
Start date
2011-02-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine without aura. Migraine: . aura without headache · basilar· equivalents familial hemiplegic · with: acute-onset aura · prolonged aura · typical aura

Interventions

Intervention 1: In a case group: Patient received Nortriptyline 10 mg nightly and Sodium valproate 200 mg daily and for dispepsia received omeprazole 20 mg and Bismuth Subcitrate 120mg twice daily, M
Treatment - Drugs
In a case group: Patient received Nortriptyline 10 mg nightly and Sodium valproate 200 mg daily and for dispepsia received omeprazole 20 mg and Bismuth Subcitrate 120mg twice daily, Metronidazole 250
Control group received Nortriptyline 10 mg nightly and Sodium valproate 200 mg daily

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Ideoathic headache 2- Age over 20 years old 3- Dyspepsia 4- IgG against H.pylori over 30u/m Exclusion criteria: 1- Classic treatment for H.pylori in 6-3 months ago 2- Uses of ß-blockers or calcium channel blockers in last month 3- Uses of antipsycotic drugs in last month 4- Uses of antiepilepthic drugs in last month 5- Pregnancy 6- Have controindication to antibiotic against H.pylori 7- Disinclination to continue the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical improvement and result of serologic test. Timepoint: In beginning of the study and the end of month one clinical evaluation. Method of measurement: Patient history and physical exam and MIDAS questionare.

Secondary

MeasureTime frame
Failure to treatment. Timepoint: End of treatment. Method of measurement: Clinical AND Serological evaluation.;Drug side effects. Timepoint: During treatment. Method of measurement: Clinical evaluation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Nader Zarinfar

Arak University of Medical Sciences

zarinfar@arakmu.ac.ir+98 86 1224 1411

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026